Minimally invasive robotic assisted thoracoscopic surgery has evolved as a safe and efficacious procedure for patients with lung and pleural diseases in the United States and Europe. Through small incisions, surgeons are able to control a variety of instruments to excise lung and mediastinal cancers with three-dimensional magnified vision, seven degrees of freedom of movement and increased precision with reduced tremor.
Associate Professor Christopher Cao has led a team of leading international thoracic surgeons and medical lung cancer specialists to establish the largest international database to date to study the safety of robotic surgery for patients with lung cancer. These studies were conducted in “Memorial Sloan Kettering Cancer Center” in the United States, the largest cancer institution in the world. In addition, the studies were published in three top international journals in 2019. With support from The Baird Institute, we are analysing our own surgical results from Royal Prince Alfred Hospital to improve the clinical outcomes of patients who undergo robotic cardiothoracic surgery. Our aim is to deliver cutting edge technology to minimise risks to patients.
